organization · Reporting owner
Boxer Asset Management Inc.
Disclosed activity across 10 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | See remarks | January 23, 2024 | January 25, 2024 |
| Odonate Therapeutics, Inc.ODT · Entity 132524 | 10% owner | November 22, 2021 | November 24, 2021 |
| Rain Oncology Inc.RAIN · Entity 94695 | See remarks | May 22, 2023 | May 24, 2023 |
| Solid Biosciences Inc.SLDB · Entity 4915 | 10% owner | March 04, 2019 | March 06, 2019 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | See remarks | October 13, 2023 | October 17, 2023 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | See Remarks | February 06, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 25, 2024
Jointly reported with Boxer Capital, LLC, LEWIS JOSEPH, MVA Investors, LLC, Davis Aaron I., Dissanayake Shehan Bharatha, Fuglesang Christopher, Braslyn Ltd., Lockend Five, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-01-23 · Disposition to issuer · Disposed 287,866 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-01-23 · Disposition to issuer · Disposed 203,754 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2024-01-23 · Disposition to issuer · Disposed 3,135,966 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2024-01-23 · Disposition to issuer · Disposed 30,518 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-01-23 · Disposition to issuer · Disposed 3,201,440 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-23 · Disposition to issuer · Disposed 332,809 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-01-23 · Disposition to issuer · Disposed 3,578,036 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-01-23 · Disposition to issuer · Disposed 1,413,475 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").
F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.
F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.
F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.
F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.
F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.
Odonate Therapeutics, Inc.
Report date November 22, 2021 · Filed November 24, 2021
Jointly reported with Boxer Capital, LLC, LEWIS JOSEPH
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,207,086 |
Last balance in matching sequence
After 2021-11-24 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-11-22 · Sale · Disposed 200,000 · Balance 4,407,086 F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $1.5362 to $1.5985. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, and (iv) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Row 2 · 2021-11-24 · Sale · Disposed 200,000 · Balance 4,207,086 F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $1.5479 to $1.5878. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, and (iv) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, and (iv) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital.
F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $1.5362 to $1.5985.
F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $1.5479 to $1.5878.
Rain Oncology Inc.
Report date May 22, 2023 · Filed May 24, 2023
Jointly reported with Boxer Capital, LLC, LEWIS JOSEPH, Davis Aaron I.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,152,212 |
Reported balance
After 2023-05-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-05-22 · Sale · Disposed 995,000 · Balance 1,152,212 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.30, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein F3: These securities are owned indirectly by Boxer Management and Joe Lewis, by virtue of their ownership of Boxer Capital. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.30, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein
F3: These securities are owned indirectly by Boxer Management and Joe Lewis, by virtue of their ownership of Boxer Capital.
Solid Biosciences Inc.
Report date March 04, 2019 · Filed March 06, 2019
Jointly reported with Boxer Capital, LLC, Braslyn Ltd., LEWIS JOSEPH, MVA Investors, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,923,272 |
Reported balance
Holding disclosure · report date 2019-03-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,923,272 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 11,488 |
Reported balance
Holding disclosure · report date 2019-03-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 11,488 F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 30,210 |
Reported balance
Holding disclosure · report date 2019-03-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 30,210 F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Tango Therapeutics, Inc.
Report date October 13, 2023 · Filed October 17, 2023 · Amendment
Jointly reported with Boxer Capital, LLC, Davis Aaron I., LEWIS JOSEPH, MVA Investors, LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,198,642 |
Last balance in matching sequence
After 2023-10-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-10-13 · Purchase · Acquired 750,000 · Balance 7,698,642 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.95 to $7.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Row 2 · 2023-10-16 · Purchase · Acquired 500,000 · Balance 8,198,642 F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.54 to $7.01, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 693,524 |
Reported balance
Holding disclosure · report date 2023-10-13 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance 693,524 F4: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,000 |
Reported balance
Holding disclosure · report date 2023-10-13 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 5,000 F5: These securities are owned directly by Mr. Davis. Each reporting person other than Mr. Davis disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 26,961 |
Reported balance
Holding disclosure · report date 2023-10-13 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance 26,961 F6: These securities are owned directly by Braslyn Ltd. Mr. Lewis is the sole indirect own of Braslyn Ltd. Each reporting person other than Mr. Lewis disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,988,450 |
Reported balance
Holding disclosure · report date 2023-10-13 · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · Balance 6,988,450 F7: These securities are owned directly by BCTG Holdings, LLC ("BCTG"). Boxer Capital is the majority member of BCTG and MVA Investors is a member of BCTG. Mr. Davis is a member of the investment committee of BCTG. Each reporting person disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.95 to $7.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.54 to $7.01, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F4: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F5: These securities are owned directly by Mr. Davis. Each reporting person other than Mr. Davis disclaims beneficial ownership of these securities.
F6: These securities are owned directly by Braslyn Ltd. Mr. Lewis is the sole indirect own of Braslyn Ltd. Each reporting person other than Mr. Lewis disclaims beneficial ownership of these securities.
F7: These securities are owned directly by BCTG Holdings, LLC ("BCTG"). Boxer Capital is the majority member of BCTG and MVA Investors is a member of BCTG. Mr. Davis is a member of the investment committee of BCTG. Each reporting person disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Tyra Biosciences, Inc.
Report date February 06, 2024 · Filed February 08, 2024
Jointly reported with Boxer Capital, LLC, LEWIS JOSEPH, MVA Investors, LLC, Davis Aaron I.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 85,939 |
Reported balance
After 2024-02-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-02-06 · Grant · Acquired 63,412 · Balance 85,939 F1: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 705,280 |
Reported balance
After 2024-02-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-06 · Grant · Acquired 705,280 · Balance 705,280 F3: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 6,448,359 |
Reported balance
Holding disclosure · report date 2024-02-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,448,359 F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F3: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Esperion Therapeutics, Inc.
Report date November 02, 2018 · Filed November 05, 2018
Jointly reported with Boxer Capital, LLC, LEWIS JOSEPH
Section 16 reporting ended · disclosed 2018-11-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,101,250 |
Last balance in matching sequence
After 2018-11-05 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
8 source rowsRow 1 · 2018-11-02 · Sale · Disposed 2,500 · Balance 1,198,750 F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $54.53 to $54.68. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd., (iv) Tuesday Thirteen Inc. and (v) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Row 2 · 2018-11-02 · Sale · Disposed 37,500 · Balance 1,161,250 F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $55.01 to $55.90. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd., (iv) Tuesday Thirteen Inc. and (v) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Row 3 · 2018-11-05 · Sale · Disposed 26,500 · Balance 1,134,750 F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $54.84 to $55.83. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd., (iv) Tuesday Thirteen Inc. and (v) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Row 4 · 2018-11-05 · Sale · Disposed 6,500 · Balance 1,128,250 F6: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $55.94 to $56.60. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd., (iv) Tuesday Thirteen Inc. and (v) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Row 5 · 2018-11-05 · Sale · Disposed 2,000 · Balance 1,126,250 F7: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $57.00 to $57.78. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd., (iv) Tuesday Thirteen Inc. and (v) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Row 6 · 2018-11-05 · Sale · Disposed 6,390 · Balance 1,119,860 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd., (iv) Tuesday Thirteen Inc. and (v) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Row 7 · 2018-11-05 · Sale · Disposed 13,610 · Balance 1,106,250 F8: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $59.37 to $59.65. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd., (iv) Tuesday Thirteen Inc. and (v) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Row 8 · 2018-11-05 · Sale · Disposed 5,000 · Balance 1,101,250 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd., (iv) Tuesday Thirteen Inc. and (v) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd., (iv) Tuesday Thirteen Inc. and (v) Joseph C. Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
F2: These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital.
F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $54.53 to $54.68.
F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $55.01 to $55.90.
F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $54.84 to $55.83.
F6: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $55.94 to $56.60.
F7: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $57.00 to $57.78.
F8: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $59.37 to $59.65.
PMV Pharmaceuticals, Inc.
Report date September 25, 2020 · Filed September 29, 2020
Jointly reported with Boxer Capital, LLC, LEWIS JOSEPH, MVA Investors, LLC, Davis Aaron I.
Section 16 reporting ended · disclosed 2020-09-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,268,236 |
Last balance in matching sequence
After 2020-09-29 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2020-09-25 · Purchase · Acquired 950,000 · Balance 950,000 F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Row 2 · 2020-09-29 · Conversion · Acquired 586,099 · Balance 1,536,099 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Row 3 · 2020-09-29 · Conversion · Acquired 732,137 · Balance 2,268,236 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,837 |
Last balance in matching sequence
After 2020-09-29 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 4 · 2020-09-29 · Conversion · Acquired 32,708 · Balance 32,708 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 5 · 2020-09-29 · Conversion · Acquired 28,129 · Balance 60,837 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-09-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-09-29 · Conversion · Disposed 586,099 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-09-29 · Conversion · Disposed 32,708 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-09-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-09-29 · Conversion · Disposed 732,137 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-09-29 · Conversion · Disposed 28,129 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.
F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Pandion Therapeutics, Inc.
Report date July 21, 2020 · Filed July 21, 2020
Jointly reported with Boxer Capital, LLC, Braslyn Ltd., LEWIS JOSEPH, Davis Aaron I., MVA Investors, LLC
Section 16 reporting ended · disclosed 2020-07-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,107,513 |
Last balance in matching sequence
After 2020-07-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-07-21 · Conversion · Acquired 1,385,291 · Balance 1,385,291 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 3 · 2020-07-21 · Purchase · Acquired 722,222 · Balance 2,107,513 F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 23,622 |
Reported balance
After 2020-07-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-07-21 · Conversion · Acquired 23,622 · Balance 23,622 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-21 · Conversion · Disposed 7,064,136 · Balance 0 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-07-21 · Conversion · Disposed 120,460 · Balance 0 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
iTeos Therapeutics, Inc.
Report date May 10, 2024 · Filed May 14, 2024
Jointly reported with Boxer Capital, LLC, LEWIS JOSEPH, Davis Aaron I.
Section 16 reporting ended · disclosed 2022-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,946,915 |
Reported balance
After 2024-05-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-05-10 · Grant · Acquired 1,142,857 · Balance 2,946,915 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2024 Filed May 14, 2024 21:32 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantCommon Stock | 1,142,857 | $17.50 | $19,999,997.50 |
DisclosureSEC source: 0000895345-24-000172 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,946,915 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantWarrant (right to purchase) · Derivative | 705,280 | $13.01 Strike: $0.00 | $9,174,987.52 |
DisclosureSEC source: 0000895345-24-000035 · form4.xml · derivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · See Remarks Boxer Asset Management Inc. · CIK 0001465836 · See Remarks LEWIS JOSEPH · CIK 0001015747 · See Remarks MVA Investors, LLC · CIK 0001468223 · See Remarks Davis Aaron I. · CIK 0001465914 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705,280 Underlying: Common Stock · 705,280 shares Expires not disclosed F3 · derivative.exercise_date: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date. F3 · derivative.expiration_date: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 63,412 | $13.01 | $824,990.12 |
DisclosureSEC source: 0000895345-24-000035 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See Remarks Boxer Asset Management Inc. · CIK 0001465836 · See Remarks LEWIS JOSEPH · CIK 0001015747 · See Remarks MVA Investors, LLC · CIK 0001468223 · See Remarks Davis Aaron I. · CIK 0001465914 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 85,939 F1 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerWarrant (right to purchase) · Derivative | 1,413,475 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · derivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,413,475 shares Expires not disclosed F7 · kind: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F7 · price: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8 · derivative.expiration_date: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5 · ownership.nature: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerWarrant (right to purchase) · Derivative | 3,578,036 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · derivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 3,578,036 shares Expires not disclosed F7 · kind: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F7 · price: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8 · derivative.expiration_date: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5 · ownership.nature: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerWarrant (right to purchase) · Derivative | 332,809 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · derivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 332,809 shares Expires not disclosed F7 · kind: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F7 · price: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8 · derivative.expiration_date: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 30,518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F6 · ownership.nature: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 3,135,966 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F5 · ownership.nature: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 203,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F4 · ownership.nature: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 3,201,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:32 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 287,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000895345-24-000019 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Braslyn Ltd. · CIK 0001642355 · See remarks Lockend Five, LLC · CIK 0001830602 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F2 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 19:41 UTC Amendment | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 500,000 | $6.84 | $3,420,000.00 |
DisclosureSEC source: 0000895345-23-000589 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,198,642 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.54 to $7.01, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 18:04 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 500,000 | $6.84 | $3,420,000.00 |
DisclosureSEC source: 0000895345-23-000588 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,198,642 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.54 to $7.01, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 19:41 UTC Amendment | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 750,000 | $7.07 | $5,302,500.00 |
DisclosureSEC source: 0000895345-23-000589 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,698,642 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.95 to $7.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 18:04 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 750,000 | $7.07 | $5,302,500.00 |
DisclosureSEC source: 0000895345-23-000588 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,698,642 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.95 to $7.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| October 09, 2023 Filed Oct 11, 2023 21:22 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 175,000 | $9.97 | $1,744,750.00 |
DisclosureSEC source: 0000895345-23-000574 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,948,642 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.6943 to $10.1829, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| October 09, 2023 Filed Oct 11, 2023 21:22 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 50,000 | $9.91 | $495,500.00 |
DisclosureSEC source: 0000895345-23-000574 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 693,524 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 9.6500 to $9.9800, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:28 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 219,638 | $16.87 | $3,705,293.06 |
DisclosureSEC source: 0000895345-23-000524 · form4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,804,058 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.50 to $17.04, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:28 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 95,516 | $15.63 | $1,492,915.08 |
DisclosureSEC source: 0000895345-23-000524 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,023,696 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.05 to $15.85, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:28 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 34,846 | $14.19 | $494,464.74 |
DisclosureSEC source: 0000895345-23-000524 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,119,212 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.80 to $14.59, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:39 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 1,201,440 | $27.80 | $33,400,032.00 |
DisclosureSEC source: 0000895345-23-000500 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,201,440 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:39 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 57,533 | $27.80 | $1,599,417.40 |
DisclosureSEC source: 0000895345-23-000500 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 287,866 F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. F1 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:38 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 1,201,440 | $27.80 | $33,400,032.00 |
DisclosureSEC source: 0000895345-23-000499 · form4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,201,440 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:38 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | PurchaseCommon Stock | 57,533 | $27.80 | $1,599,417.40 |
DisclosureSEC source: 0000895345-23-000499 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Dissanayake Shehan Bharatha · CIK 0001663609 · See remarks Fuglesang Christopher · CIK 0001465835 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 287,866 F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. F1 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:34 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchasePrefunded Warrant · Derivative | 2,340,579 | $5.15 | $12,053,747.79 |
DisclosureSEC source: 0000895345-23-000498 · form4.xml · derivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,340,597 Underlying: Common Stock · 2,340,579 shares Expires not disclosed F6 · derivative.exercise_price: The prefunded warrants have an exercise price of $0.001 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F6 · derivative.exercise_date: The prefunded warrants have an exercise price of $0.001 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F6 · derivative.expiration_date: The prefunded warrants have an exercise price of $0.001 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:34 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 475,000 | $5.15 | $2,446,250.00 |
DisclosureSEC source: 0000895345-23-000498 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks MVA Investors, LLC · CIK 0001468223 · See remarks Davis Aaron I. · CIK 0001465914 · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 743,542 F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. F1 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Oct 11, 2023 19:22 UTC Amendment | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantPrefunded Warrant · Derivative | 2,340,579 | $5.15 | $12,053,747.79 |
DisclosureSEC source: 0000895345-23-000573 · form4.xml · derivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · Director · See remarks Boxer Asset Management Inc. · CIK 0001465836 · Director · See remarks LEWIS JOSEPH · CIK 0001015747 · Director · See remarks MVA Investors, LLC · CIK 0001468223 · Director · See remarks Davis Aaron I. · CIK 0001465914 · Director · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,340,579 Underlying: Common Stock · 2,340,579 shares Expires not disclosed F6 · derivative.exercise_price: The prefunded warrants have an exercise price of $0.001 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F6 · derivative.exercise_date: The prefunded warrants have an exercise price of $0.001 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F6 · derivative.expiration_date: The prefunded warrants have an exercise price of $0.001 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Oct 11, 2023 19:22 UTC Amendment | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 475,000 | $5.15 | $2,446,250.00 |
DisclosureSEC source: 0000895345-23-000573 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · Director · See remarks Boxer Asset Management Inc. · CIK 0001465836 · Director · See remarks LEWIS JOSEPH · CIK 0001015747 · Director · See remarks MVA Investors, LLC · CIK 0001468223 · Director · See remarks Davis Aaron I. · CIK 0001465914 · Director · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 743,542 F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. F1 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| May 22, 2023 Filed May 24, 2023 20:05 UTC | Rain Oncology Inc. RAIN · Entity 94695 | SaleCommon Stock | 995,000 | $1.25 | $1,243,750.00 |
DisclosureSEC source: 0000895345-23-000356 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks. Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks. Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,152,212 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.30, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein F3 · ownership.direct: These securities are owned indirectly by Boxer Management and Joe Lewis, by virtue of their ownership of Boxer Capital. Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 21:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 70,000 | $4.65 | $325,227.00 |
DisclosureSEC source: 0000899243-22-033595 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,123,642 F2 · ownership.direct: These securities are owned directly by Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 21:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 50,000 | $4.43 | $221,640.00 |
DisclosureSEC source: 0000899243-22-033595 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,524 F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC ("Boxer Capital"), (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) BCTG Holdings, LLC, (v) MVA Investors and (vi) Aaron I. Davis (collectively, the "Boxer Group"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 21:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 117,000 | $4.25 | $497,706.30 |
DisclosureSEC source: 0000899243-22-033595 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,524 F3 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $4.0500 to $4.2631. F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC ("Boxer Capital"), (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) BCTG Holdings, LLC, (v) MVA Investors and (vi) Aaron I. Davis (collectively, the "Boxer Group"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 06, 2022 Filed Oct 6, 2022 21:15 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 70,394 | $4.06 | $286,067.14 |
DisclosureSEC source: 0000899243-22-033177 · doc4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,053,642 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) BCTG Holdings, LLC, (v) MVA Investors, LLC, and (vi) Aaron I. Davis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 21:15 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 40,500 | $3.84 | $155,410.65 |
DisclosureSEC source: 0000899243-22-033177 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,983,248 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) BCTG Holdings, LLC, (v) MVA Investors, LLC, and (vi) Aaron I. Davis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 21:15 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 45,500 | $3.93 | $178,642.10 |
DisclosureSEC source: 0000899243-22-033177 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,942,748 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) BCTG Holdings, LLC, (v) MVA Investors, LLC, and (vi) Aaron I. Davis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 21:15 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 25,606 | $3.67 | $93,976.58 |
DisclosureSEC source: 0000899243-22-033177 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,897,248 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) BCTG Holdings, LLC, (v) MVA Investors, LLC, and (vi) Aaron I. Davis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 21:00 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 575,201 | $35.25 | $20,275,835.25 |
DisclosureSEC source: 0000899243-22-011657 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,142,058 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, and (iv) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 2,517 | $45.48 | $114,467.37 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 14 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 11,199 | $44.44 | $497,701.48 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 13 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,517 F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 3,138 | $43.36 | $136,062.42 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 12 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,716 F6 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221. F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 29,623 | $41.84 | $1,239,485.57 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 11 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,854 F5 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440. F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 7,483 | $45.48 | $340,309.63 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 10 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,717,259 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 33,297 | $44.44 | $1,479,771.96 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 9 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,724,742 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 9,366 | $43.36 | $406,109.76 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,758,039 F6 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 88,054 | $41.84 | $3,684,355.47 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,767,405 F5 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 731 | $50.63 | $37,013.31 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,477 F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 1,682 | $49.37 | $83,048.58 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,208 F4 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716. F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 23,353 | $47.63 | $1,112,245.01 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,890 F3 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617. F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 17,173 | $50.63 | $869,534.25 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,855,459 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 39,481 | $49.37 | $1,949,354.63 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,872,632 F4 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.